By addressing the issues of potency and metabolism in 3, a new series
of LTD, antagonists represented by (+)-26 was developed which is equip
otent to clinical LTD, antagonists Zafirlukast (1) and Pranlukast (2).
(C) 1998 Elsevier Science Ltd. All rights reserved.